Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.

Vaccine·2026
Same author

Antibodies against polysaccharide type 3 and pneumococcal proteins demonstrate synergistic protective effect in a highly virulent type 3 invasive disease model in mice.

Frontiers in immunology·2025
Same author

A 15-year Single-center Analysis of Late-onset Group B Streptococcus Infection Correlating Clinical Severity With Pathogen Virulence Determinants.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Longitudinal Antibody Responses to SARS-CoV-2 Infection in Children: Impact of Age, Vaccines and Symptoms.

The Pediatric infectious disease journal·2025
Same author

Novel <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> MAPS vaccine combining O polysaccharides and pathogen-specific proteins.

mBio·2025
Same author

CC180 clade dynamics do not universally explain Streptococcus pneumoniae serotype 3 persistence post-vaccine: a global comparative population genomics study.

EBioMedicine·2025
Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026
Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026
Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026
Same journal

On or within: spatial determinants of antigen handling in the nasal turbinates.

Current opinion in immunology·2026
Same journal

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
Same journal

Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection.

Current opinion in immunology·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Next generation pneumococcal vaccines.

Kristin L Moffitt1, Richard Malley

  • 1Division of Infectious Diseases, Children's Hospital, Harvard Medical School, Boston, MA, United States.

Current Opinion in Immunology
|April 26, 2011
PubMed
Summary
This summary is machine-generated.

Current pneumococcal vaccines are costly and cover limited serotypes. This review explores alternative strategies like conjugate, protein-based, and whole-cell vaccines to improve global access and efficacy against pneumococcal disease.

More Related Videos

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Related Experiment Videos

Last Updated: Jun 2, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction
04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Pneumococcal vaccines are crucial for preventing Streptococcus pneumoniae infections.
  • Current vaccines rely on polysaccharide antigens, but have limitations in serotype coverage and cost.
  • High cost and limited serotype coverage restrict global use, especially in low-resource settings.

Purpose of the Study:

  • To review alternative and adjunctive strategies for pneumococcal vaccines.
  • To discuss novel vaccine approaches beyond traditional polysaccharide-based vaccines.
  • To explore the immunological underpinnings of emerging pneumococcal vaccine technologies.

Main Methods:

  • Review of current literature on pneumococcal vaccine development.
  • Analysis of polysaccharide-protein conjugate strategies.
  • Evaluation of protein-based and whole-cell pneumococcal vaccine approaches.

Main Results:

  • Polysaccharide-protein conjugate vaccines offer broader serotype coverage.
  • Protein-based vaccines present a promising alternative with potential for improved immunogenicity.
  • Whole-cell vaccines are being re-evaluated for their potential as broad-spectrum options.

Conclusions:

  • Novel pneumococcal vaccine strategies are essential to overcome limitations of current vaccines.
  • Conjugate, protein-based, and whole-cell vaccines represent diverse avenues for improved pneumococcal disease prevention.
  • Further research into the immunological mechanisms of these alternative vaccines is warranted for global health impact.